Back to Search
Start Over
ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement
- Source :
- Business Wire. January 17, 2024
- Publication Year :
- 2024
-
Abstract
- * License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness DUBLIN, Ireland & TAMPERE, Finland -- ERS Genomics Limited ('ERS'), [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.779571515